SequelSEC

BIOTRICITY INC. BTCY

Surgical & Medical Instruments & Apparatus · CIK 0001630113 · Fiscal year ends 0331

AnnualQuarterlyTTM
Revenue
$16.00M
Fiscal year ended 2026-03-31
Operating income
$1.69M
Fiscal year ended 2026-03-31
Free cash flow
Unavailable
Fiscal year ended 2026-03-31

BIOTRICITY INC. (BTCY) reported revenue of $16.00M and net income of -$2.40M for the fiscal year ended 2026-03-31. This page shows 8 annual periods of income statement, balance sheet and cash flow figures normalized from BIOTRICITY INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Surgical & Medical Instruments & Apparatus.

Income

BIOTRICITY INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-03-312025-03-312024-03-312023-03-312022-03-312021-03-312020-03-312019-03-31
Revenue$16.00M$13.79M$12.06M$9.64M$7.65M$3.38M$1.42M$398.20K
Cost of revenue$3.05M$3.23M$3.71M$4.20M$3.08M$2.11M$931.95K$338.34K
Gross profit$12.95M$10.56M$8.36M$5.44M$4.57M$1.27M$485.77K$59.86K
Operating income$1.69M-$2.45M-$8.83M-$15.41M-$16.74MUnavailableUnavailableUnavailable
Net income-$2.40M-$8.42M-$14.09M-$18.66M-$29.13M-$15.49M-$11.07M-$8.59M
Research & development$2.76M$2.16M$2.57M$3.23M$2.74M$2.06M$1.36M$1.31M
Weighted-average diluted sharesshares 27.30Mshares 21.52Mshares 8.99Mshares 8.66MUnavailableUnavailableUnavailableUnavailable
Pretax income-$2.40M-$8.42M-$14.09M-$18.66M-$29.13M-$15.49M-$11.07M-$8.59M
Income tax expenseUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Diluted EPS$-0.12$-0.56$-1.66$-2.26UnavailableUnavailableUnavailableUnavailable
Selling, general & administrative$8.49M$10.86M$14.61M$17.62M$18.56MUnavailableUnavailableUnavailable
General & administrativeUnavailableUnavailableUnavailableUnavailable$19.85M$12.57M$10.05M$7.34M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

BIOTRICITY INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-03-312025-03-312024-03-312023-03-312022-03-312021-03-312020-03-312019-03-31
Cash & equivalents$149.79K$365.14K$786.06K$570.46K$12.07M$2.20M$949.85K$63.65K
Total assets$6.45M$5.64M$5.94M$6.51M$16.68M$4.44M$2.00M$490.66K
Current assets$5.86M$4.64M$4.47M$4.72M$15.32M$4.32M$1.66M$457.66K
Total liabilities$39.41M$35.66M$35.92M$26.36M$18.82M$11.27M$5.00M$2.27M
Current liabilities$37.14M$20.64M$22.70M$11.16M$4.87M$10.49M$3.80M$2.27M
Total equity incl. NCI-$34.68M-$32.01M-$31.47M-$19.85M-$2.14M-$6.83M-$3.00M-$1.78M
Temporary (mezzanine) equity$1.71M$2.00M$1.49MUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$1.34M$1.56M$1.88M$2.34M$842.92K$272.49K$85.72K$24.60K
Accounts receivable$2.93M$1.66M$1.47M$1.22M$2.01M$1.52M$486.19K$208.10K
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payableUnavailableUnavailableUnavailableUnavailableUnavailable$1.04M$1.09M$878.45K

Cash flow

BIOTRICITY INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-03-312025-03-312024-03-312023-03-312022-03-312021-03-312020-03-312019-03-31
Operating cash flow-$718.96K-$2.38M-$6.69M-$13.55M-$15.16M-$11.08M-$7.86M-$5.22M
Capital expendituresUnavailableUnavailableUnavailableUnavailable$29.77KUnavailableUnavailableUnavailable
Investing cash flowUnavailableUnavailableUnavailableUnavailable-$29.77KUnavailableUnavailableUnavailable
Financing cash flow$557.74K$1.93M$6.74M$2.00M$25.17M$12.20M$8.88M$4.56M
Net change in cashUnavailable-$450.92K$47.77KUnavailableUnavailable$1.19M$1.02M-$664.30K
Stock-based compensation$25.63K$1.46M$1.03M$647.63K$913.61K$790.54K$2.41M$1.45M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailable$602.97K$180.00KUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailable$2.48M$92.42KUnavailable

Derived

BIOTRICITY INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-03-312025-03-312024-03-312023-03-312022-03-312021-03-312020-03-312019-03-31
Free cash flowUnavailableUnavailableUnavailableUnavailable-$15.19MUnavailableUnavailableUnavailable
Gross margin80.9%76.6%69.3%56.5%59.7%37.6%34.3%15.0%
Operating margin10.6%-17.8%-73.2%-159.9%-218.8%UnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailable-198.6%UnavailableUnavailableUnavailable
SBC / revenue0.2%10.6%8.5%6.7%11.9%23.4%169.9%364.5%
Current ratio0.16x0.22x0.20x0.42x3.15x0.41x0.44x0.20x
Revenue YoY growth16.0%14.3%25.2%26.0%126.0%138.7%256.0%Unavailable
Net margin-15.0%-61.1%-116.8%-193.6%-380.8%-457.7%-780.6%-2157.7%
R&D / revenue17.3%15.6%21.3%33.5%35.9%60.8%96.2%328.8%
CapEx / revenueUnavailableUnavailableUnavailableUnavailable0.4%UnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open BTCY in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-19View SEC filing
10-K · Filed 2026-07-14View SEC filing
10-Q · Filed 2026-02-11View SEC filing
10-Q · Filed 2025-11-14View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-K/A · Filed 2025-07-18View SEC filing

Companies in the same industry

ADGM AEMD ALUR AMIX ANGO ANIK AORT APYX ARAY ATEC ATRC AURX

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.